The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia
- PMID: 33422890
- PMCID: PMC7902470
- DOI: 10.1016/j.neurobiolaging.2020.12.009
The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia
Abstract
Reduced nigrostriatal uptake on N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-[123I]iodophenyl) nortropane (123I-FP-CIT) SPECT reflects dopamine dysfunction, while other imaging markers could be complementary when used together. We assessed how well 123I-FP-CIT SPECT differentiates dementia with Lewy bodies (DLBs) from Alzheimer's disease dementia (ADem) and whether multimodal imaging provides additional value. 123I-FP-CIT SPECT, magnetic resonance imaging, [18F]2-fluoro-deoxy-D-glucose-positron emission tomography (PET), and 11C-Pittsburgh compound B (PiB)-PET were assessed in 35 participants with DLBs and 14 participants with ADem (autopsy confirmation in 9 DLBs and 4 ADem). Nigrostriatal dopamine transporter uptake was evaluated with 123I-FP-CIT SPECT using DaTQUANT software. Hippocampal volume was calculated with magnetic resonance imaging, cingulate island sign ratio with FDG-PET, and global cortical PiB retention with PiB-PET. The DaTQUANT z-scores of the putamen showed the highest c-statistic of 0.916 in differentiating DLBs from ADem among the analyzed imaging biomarkers. Adding another imaging modality to 123I-FP-CIT SPECT had c-statistics ranging from 0.968 to 0.975, and 123I-FP-CIT SPECT in combination with 2 other imaging modalities presented c-statistics ranging from 0.987 to 0.996. These findings suggest that multimodal imaging with 123I-FP-CIT SPECT aids in differentiating DLBs and ADem and in detecting comorbid Lewy-related and Alzheimer's disease pathology in patients with DLBs and ADem.
Keywords: (123)I-FP-CIT SPECT; DaTQUANT; Dementia with Lewy bodies; FDG-PET; MRI; PiB-PET.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures
Declarations of interest: none
Figures



Similar articles
-
Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders.J Nucl Med. 2020 Nov;61(11):1628-1635. doi: 10.2967/jnumed.119.239418. Epub 2020 Mar 20. J Nucl Med. 2020. PMID: 32198310 Free PMC article.
-
Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.Arch Neurol. 2004 Jun;61(6):919-25. doi: 10.1001/archneur.61.6.919. Arch Neurol. 2004. PMID: 15210531
-
(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study.Ann Neurol. 2016 Sep;80(3):368-78. doi: 10.1002/ana.24717. Epub 2016 Aug 2. Ann Neurol. 2016. PMID: 27398636
-
[123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies.Alzheimers Dement. 2012 Jan;8(1):74-83. doi: 10.1016/j.jalz.2011.08.003. Epub 2011 Oct 22. Alzheimers Dement. 2012. PMID: 22024052 Review.
-
[The applicability of 123I-FP-CIT SPECT dopamine transporter imaging in clinical practice].Ideggyogy Sz. 2019 Nov 30;72(11-12):381-388. doi: 10.18071/isz.72.0381. Ideggyogy Sz. 2019. PMID: 31834681 Review. Hungarian.
Cited by
-
Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review.Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):1876-1890. doi: 10.1007/s00259-024-06631-y. Epub 2024 Feb 15. Eur J Nucl Med Mol Imaging. 2024. PMID: 38355740
-
Comparative analysis of white matter signal alterations in dementia with Lewy bodies and Alzheimer's disease: a systematic review and meta-analysis.Front Radiol. 2025 Apr 4;5:1554345. doi: 10.3389/fradi.2025.1554345. eCollection 2025. Front Radiol. 2025. PMID: 40256257 Free PMC article.
-
Recent progress in the applications of presynaptic dopaminergic positron emission tomography imaging in parkinsonism.Neural Regen Res. 2025 Jan 1;20(1):93-106. doi: 10.4103/1673-5374.391180. Epub 2023 Dec 21. Neural Regen Res. 2025. PMID: 38767479 Free PMC article.
-
Marked Decreased Tracer Binding in 123 I-FP-CIT SPECT Scans From Lisdexafetamine Dismesylate Interaction: A Case Report.Clin Neuropharmacol. 2024 Jan-Feb 01;47(1):26-28. doi: 10.1097/WNF.0000000000000579. Epub 2024 Feb 2. Clin Neuropharmacol. 2024. PMID: 38193851 Free PMC article.
-
The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review.Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):1988-2035. doi: 10.1007/s00259-023-06154-y. Epub 2023 Mar 15. Eur J Nucl Med Mol Imaging. 2023. PMID: 36920494 Free PMC article.
References
-
- Albin RL, Minoshima S, D’Amato CJ, Frey KA, Kuhl DA, Sima AA, 1996. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 47(2), 462–466. - PubMed
-
- Ashburner J, Friston KJ, 2005. Unified segmentation. Neuroimage 26(3), 839–851. - PubMed
-
- Barber R, Ballard C, McKeith IG, Gholkar A, O’Brien JT, 2000. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 54(6), 1304–1309. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical